Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -4 of 4 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/8/2007 First Published: 8/24/2003


1.		Phase III Randomized Study of Monoclonal Antibody B43.13 in Patients With Stage III or IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0211008 UNITHER-OVA-Gy-17(A), NCT00050375

Last Modified: 5/31/2007 First Published: 1/1/1999


2.		Phase IIB Randomized Study of OvaRex Monoclonal Antibody B43.13 as Post Chemotherapy Consolidation in Patients With Stage III or IV Ovarian Epithelial, Tubal, or Peritoneal Adenocarcinoma (Summary Last Modified 04/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				ALTAREX-OVA-Gy-07 ALTAREX-961452, ALTAREX-OVA-Gy-06, NCI-V98-1488, NCT00003634

Last Modified: 6/1/2007 First Published: 10/1/1999


3.		Phase II Randomized Study of OvaRex Monoclonal Antibody B43.13 in Patients with Epithelial Adenocarcinoma of the Ovary, Fallopian Tube, or Peritoneum and Elevated Serum CA 125, But Without Other Evidence of Disease (Summary Last Modified 07/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				ALTAREX-OVA-Gy-10 OU-08111, NCT00004064

Last Modified: 12/12/2007 First Published: 10/23/2007


4.		Randomized Pilot Study of Consolidation Therapy Comprising Adjuvant Oregovomab With Versus Without Cyclophosphamide in Patients With Stage III or IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Adenocarcinoma That Responded to Second-Line Taxane/Platinum-Based Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Biomarker/Laboratory analysis, Treatment				Temporarily closed				18 and over				NCI				GOG-0243 GOG-0243, NCT00551265

Select All on One Page